Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A 24-Week, Multicentre, Randomised, Double-Blind,

To see complete record on, please visit this link

Id: 2021-006200-33

Organisation Name: Clairvoyant Therapeutics Inc.

Start Date: 2022-09-22

Completion Date: Ongoing

Brief Summary: The primary objective of the trial is to evaluate the efficacy of 25 mg Psilocybin vs Placebo in subjects with alcohol use disorder (AUD) with number of heavy drinking days (HDD) over the 8-week treatment period, measured on a monthly basis relative to baseline (Visit 1 - 5).

Country: Canada

Total execution time in seconds: 0.18208789825439